-The Times of India NEW DELHI: The health ministry was actively mulling compulsory licensing, apart from price capping, of “orphan drugs” (for rare diseases), when the department of pharmaceuticals abruptly issued an order exempting such medicines from price control, derailing plans to make these drugs affordable. The health ministry discussed price capping and invoking compulsory licence for these “exorbitantly” priced “orphan drugs” at a meeting on January 3, the day when DoP...

-Frontline.in The Assembly elections have put under intense scrutiny Narendra Modi’s Gujarat model of development which is touted as worthy of replication throughout the country. Audit reports of the CAG provide ample evidence of it being inefficient, corrupt and not beneficial to the common people. THE standard indicators of development, as is understood in theory and practice, comprise a range of indices, and not necessarily the level of private investment in...

-The Hindu Business Line Public procurement at a negotiated price is a better option. Price curbs deter producers and don’t check pharmacy margins The Government’s attempt to keep the prices of essential medicines affordable and curb the extraordinary returns earned by private healthcare providers through price controls has started an inexorable process whose end does not seem in sight. Will these moves eventually be counter-productive? First came the move to extend the scope...

-Livemint.com Govt plans to?help firms revamp manufacturing units,?refurbish machinery,?ensure subsidized power in bid to produce drugs such as penicillin at competitive rates New Delhi: The Department of Pharmaceuticals (DoP), during a meeting on Wednesday, urged pharma companies to strive for self-sufficiency in critical drugs like penicillin, rifampicin and insulin, in a sign of government concern over India’s dependence on Chinese imports. A large number of so-called active pharmaceutical ingredients (APIs), or bulk drugs,...

-TheWire.in The government’s premier policy-formulating agency recently recommended measures to deregulate the pharmaceutical sector and make essential medicines more expensive. New Delhi: Even as the prime minister repeatedly expresses his commitment to providing affordable medicines in the country, it appears that the NITI Aayog and the Department of Pharmaceuticals (DoP) may be working in an opposing direction. Documents between October 2016 and April 2017 show the intention of various government arms to...